Jane Street Group, LLC Nektar Therapeutics Put Options Transaction History

Jane Street Group, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 17, 2022	BUY	$4.16 - $13.72 $2.45 Million - $8.08 Million	588,900 Added 1702.02%	623,500 $3.36 Million
Q4 2021 Feb 15, 2022	BUY	$10.83 - $18.41 $233,928 - $397,656	21,600 Added 166.15%	34,600 $467,000
Q3 2021 Nov 16, 2021	SELL	$13.07 - $18.84 $377,723 - $544,476	-28,900 Reduced 68.97%	13,000 $233,000
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $113,988 - $140,760	6,900 Added 19.71%	41,900 $719,000
Q4 2020 Feb 17, 2021	BUY	$15.77 - $19.03 $364,287 - $439,593	23,100 Added 194.12%	35,000 $595,000
Q2 2020 Aug 17, 2020	SELL	$16.86 - $23.44 $195,576 - $271,904	-11,600 Reduced 49.36%	11,900 $276,000
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $39,069 - $75,492	2,700 Added 12.98%	23,500 $419,000
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $182,628 - $391,716	-10,800 Reduced 34.18%	20,800 $379,000
Q2 2018 Aug 15, 2018	BUY	$46.25 - $104.45 $948,125 - $2.14 Million	20,500 Added 184.68%	31,600 $1.54 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $287,000 - $542,200	5,000 Added 81.97%	11,100 $1.18 Million
Q4 2017 Feb 15, 2018	BUY	$23.02 - $60.5 $140,422 - $369,050	6,100	6,100 $364,000

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $197M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.